A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Patents | February 13, 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. The present disclosure relates to non-hemolytic blood compatible devices and methods for capture, enumeration, removal of disease-causing agents from the blood and for the treatment of the cancer patients. The said devices incorporating non-hemolytic compositions are useful for removing disease-causing agents 'ex vivo' from cancer patient's blood to prevent/delay the proliferation of cancer. The devices retain disease-causing agents in particular Circulating Tumor Cells (CTCs), allowing the passage of other blood constituents retaining the viability of hematopoietic cells. Related patent documents WO/2023/229674 CA3255372 IN202527040253 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius will present seven poster presentations at ISLB 2026 in Madrid, covering liquid biopsy, CTCs, treatment monitoring, biomarkers, residual disease and metastasis research. Events | August 30, 2026 ISLB Annual Congress 2026 | 7-9 November | Madrid, Spain Actorius will present seven scientific posters at ISLB 2026 in Madrid, showcasing research advancing the clinical potential of CTCs across treatment monitoring, biomarker analysis, residual disease, and metastasis research. Seven studies. One shared goal: advancing the clinical potential of circulating tumor cells. This November, at ISLB 2026 in Madrid , Actorius will present seven scientific posters at the International Society of Liquid Biopsy Congress—the highest number of accepted posters from any academic group or company. Our team will be presenting research spanning CTC biology, treatment monitoring, biomarker expression, algorithm-based analysis, minimal cellular residual disease, and extracorporeal approaches. Our Poster Presentations Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients Algorithm-Based Analysis of Circulating Tumour Cells in Cancer Patients Evaluation of Circulating Tumor Cells Expressing PD-L1 and CTC Clusters at Baseline and Follow-Ups in Triple-Negative Breast Cancer Capture of Cancerous Cells and Overall Survival in Rats Using an Ex-Vivo Extracorporeal Device in Multiple Onco-Dialysis Cycles Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells Using an Affinity-Based N-Cadherin System Assessment of Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre- and Post-Surgery Breast Cancer Patients Across these seven studies, one theme connects our work: That is making circulating tumor cells more clinically meaningful—from understanding tumor biology and treatment response to monitoring residual disease and exploring new approaches to metastasis. Meet our Founders Our three co-founders will also be at ISLB Annual congress. If you work in liquid biopsy, CTC biology, oncology research, or precision oncology, we would be glad to connect and exchange perspectives. Visit us at Booth 7 Meet us in Madrid, or book a meeting in advance actorius.com Events | Actorius Innovations and Research Discover groundbreaking events where innovation meets action in oncology. Join us to explore the future of biotechnology events today! #ISLB2026 #LiquidBiopsy #CirculatingTumorCells #CTC #PrecisionOncology #CancerResearch #OncologyResearch #Actorius #CancerDiagnostics #Metastasis Research Book appointment Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius ISLB 2025 | 1-3 November 2025 Events | November 3, 2025 ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Some glimpses from ISLB 2025 Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications | November 3, 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

AR-V7 detection in CTCs may predict ARSI resistance and guide prostate cancer therapy. Publications | August 30, 2026 Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions. Introduction: The androgen receptor (AR) is the principal driver of prostate cancer (PC) progression and the primary therapeutic target of androgen receptor signaling inhibitors (ARSIs). Androgen receptor splice variant 7 (AR-V7) is a constitutively active splice variant of AR that lacks the ligand-binding domain targeted by ARSIs, enabling persistent AR signaling despite therapy. AR-V7 has emerged as a predictive biomarker of resistance to ARSI therapy in metastatic castration-resistant prostate cancer (mCRPC), with shorter progression-free survival (PFS) and overall survival (OS) with abiraterone or enzalutamide. Detection of AR-V7 in circulating tumour cells (CTCs) is a strong predictive biomarker for identifying patients who are less likely to benefit from ARSI therapy. Dynamic treatment decisions (DTD) based on AR-V7 expression in CTCs may have significant implications for improving clinical outcomes. We evaluated AR-V7 expression in CTCs and CTC clusters from patients with prostate cancer (PC). Methods: Retrospectively, 1.5 mL of peripheral blood samples from 30 cancer patients, comprising 24 patients with advanced prostate cancer and 6 negative controls (non-PC), were processed using the CDSCO-approved OncoDiscover immunomagnetic affinity platform. CTC enrichment was performed using anti-EpCAM antibody-based immunomagnetic capture, followed by identification of CK18-positive, CD45-negative, DAPI-positive cells. CTCs and CTC clusters were immunostained with antibodies against total AR and the AR-V7 splice variant and analysed using microscopy. Individual CTCs and CTC clusters were evaluated for AR and AR-V7 expression at single-CTC resolution. Results: Among 23 patients with advanced PC, CTCs and/or CTC clusters were detected in 73.9% (17/23) of patients. A total of 31 CTCs were isolated, corresponding to a mean CTC distribution of 1.35 per patient, including 61.29% (19/31) individual CTCs and 38.70% (12/31) CTC clusters. AR-V7-positive CTCs and/or CTC clusters were detected in 43.47% (10/23) of patients. Overall, 35.5% (11/31) of CTCs were AR-V7-positive, comprising 6 individual CTCs and 5 CTC clusters. Among the 12 CTC clusters, 5 (41.7%) expressed AR-V7. Seven of 10 AR-V7-positive patients (70.0%) demonstrated both AR-V7-positive and AR-V7-negative CTCs and CTC clusters, highlighting interpatient and intrapatient heterogeneity. Conclusion: We detected AR-V7-positive CTCs and CTC clusters in patients with PC, demonstrating heterogeneity in AR-V7 expression. Further clinical studies correlating AR-V7 status with dynamic treatment decisions and therapeutic response outcomes are warranted. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

RUPIKA reduces cancer worry when communicating CTC-based minimal residual disease results. Publications | August 30, 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Introduction: Circulating tumor cells (CTCs) are increasingly used to assess minimal cellular residual disease (MCRD) in solid tumors. However, no standardized guidance exists for communicating MCRD results to patients, potentially leading to psychological distress and increased apprehension regarding residual disease after treatment, including surgery. We developed RUPIKA—Rapport, Understanding and Education, Preparation for Sample Collection, Inform Results, Kind Closure, and Advise for Follow-up—a structured communication protocol for sharing post-surgery outcomes with patients. We report an apprehension protocol for communicating MCRD outcomes in pre- and post-surgery breast cancer patients. Method: In an ongoing prospective interventional study (CTRI/2025/09/094661 and IEC SJNAHS 113/2025; St. John’s Medical College Hospital, Bengaluru, India), six oncology experts standardized the study using the ABC Content Validity Index (CVI) framework. Pre- and post-surgery, 22 patients with early-stage or in-situ stage I–III breast cancer were enrolled and equally assigned to routine disclosure (control, n=11) or RUPIKA-guided disclosure (intervention, n=11). A 1.5 mL blood sample was analyzed for CTCs (CK⁺/DAPI⁺/CD45⁻) and PD-L1 expression using the CDSCO-India-approved OncoDiscover immunomagnetic CTC platform. The six-step RUPIKA protocol included rapport building, understanding and education, preparation for sample collection, structured communication of CTC results, supportive closure, and follow-up planning. Cancer worry and apprehension were assessed before and after disclosure. The mean patient age was 52±12 years. Twenty-seven percent had early-stage/in-situ disease, with Luminal B representing the predominant molecular subtype. Most participants were from rural backgrounds, and none had prior awareness of MRD. Results: The protocol demonstrated high validity (CVI=0.98). CTCs persisted in a substantial proportion of patients (66.7%) after completion of chemotherapy and surgical intervention, suggesting the presence of MCRD. Before surgery, CTCs were detected in 83.3% of patients. After surgery, CTCs remained detectable in 66.7% of patients, while four patients became CTC-negative. Following surgery, cancer worry increased significantly in the control group (54.73±8.89; P=0.003), whereas it decreased significantly in the RUPIKA group (24.73±6.59; P<0.001). Between-group comparison showed significantly lower post-disclosure cancer worry among patients receiving RUPIKA-guided counselling compared with routine disclosure (t=8.992; P<0.001). Conclusion: This ongoing observational study demonstrates that RUPIKA—the first dedicated CTC-based MRD disclosure protocol—effectively mitigates cancer worry in breast cancer patients. Larger studies across diverse cancer cohorts are warranted. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Meeting with Oncology KOLs in US and Europe Events | February 20, 2026 Meeting with our KOLs Our team meeting with oncology KOLs from the US and Europe. Meeting with Oncology KOLs in USA and Europe We had the opportunity to engage with leading oncology KOLs across the USA and Europe, including Dr. Klaus Pantel , Dr. Catherine Alix-Panabières , Dr. Umberto Malapelle , and Dr. Ravindra Kolhe . The discussions centered around our latest innovation, OncoMetastat® , and explored emerging advancements in oncology—particularly in circulating tumor cell (CTC) research and the biology of metastasis. OncoMetastat® is our patented investigational extracorporeal blood-processing platform, inspired by blood-dialysis principles. It is designed to selectively capture circulating tumor cells directly from a patient’s bloodstream while preserving overall blood integrity. By enabling real-time interaction with CTCs, the platform aims to go beyond detection—offering the potential to study tumor behavior dynamically and generate deeper biological insights into disease progression. Importantly, OncoMetastat® is also being evaluated for its potential to reduce circulating tumor burden through selective capture, opening new possibilities in adjunct therapeutic strategies and early intervention in the metastatic cascade. Built with a strong emphasis on precision, safety, and scalability, the technology represents a step toward integrating diagnostics and intervention within a single platform. These insightful exchanges with global experts reinforce our commitment to advancing precision-driven cancer care through collaboration, innovation, and a deeper understanding of cancer biology. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Expert Insights | August 9, 2022 Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

3D-printed G-EpCAM device effectively captures CTCs to stem metastatic progression. Publications | June 7, 2022 ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Background Metastatic progression accounts for nearly 90% of cancer-related deaths and has been directly correlated with the presence of circulating tumor cells (CTCs) in numerous carcinomas, including breast, lung, ovarian, colorectal, and head and neck cancers. The removal of CTCs from cancer patients' blood is directly implicated in the reduction of extravasation and disease invasiveness to secondary organs. Methods We designed and printed 3-dimensional (3D) microchannel devices using a biocompatible polymer and packed them with anti-EpCAM (EpCAM) mediated glass-based (G) compositions (G-EpCAM). Computational fluid dynamic (CFD) analysis simulation was explored to optimize the hemodynamic effect of the G-EpCAM device for measuring the pressure and velocity difference for blood along the spiral flow microchannels. Red blood cell (RBC) hemolysis was estimated using G-EpCAM compositions packed in a device to determine optimal biocompatibility. We assessed cancer cell lines' (breast cancer MCF7, lung cancer A549) interactions and capture with varying incubation time points, the effect of anti-EpCAM concentrations, the number of G-EpCAMs, and series of devices. We evaluated the G-EpCAM-on-device's CTC capture capability and biocompatibility using head and neck, colorectal, lung, and ductal breast cancer patients' blood samples. All G-EpCAM captured CTCs were immunostained for cytokeratin 18 (CK18) expression, and the optimal fluorescence acquisition intensity was quantified. Results The extracorporeal G-EpCAM microchannel device was 3D printed and consisted of an interlocking top lid and bottom base with inlet and outlet channels. The path length of the spiral device consisted of 20 microchannels with a 6.0-foot length. The device accommodated 28 gm of non-hemolytic G-EpCAM compositions. CFD analysis showed 3.8 mm as the ideal channel diameter and 2 mm as the superlative G-EpCAM diameter for maximal cell and CTC capture with minimal blood hemolysis (less than 1%) as compared to the control. Series 1 and 2 devices indicated 90% and 85% cell capture efficiency, respectively, using G-EpCAM devices, indicating the highest interactions and efficiency with cells. Conversely, the first device in the series captured the highest number of cells. In addition, the efficiency improved as the number of G-EpCAM compositions was increased. We accounted for the device to capture CTCs with specificity using the G-EpCAM composition and observed no hemolysis or non-specific interactions with other blood cells like RBCs or leukocytes. Conclusions Continuous CTC removal from cancer patients' blood circulation using such a device offers promising therapeutic utility in stemming aggressive metastatic invasion and progression for improving the overall survival of epithelial origin cancer patients. Clinical Trial Information CTRI U1111/1192-3951. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magnetic nanogels enable optimized capture of circulating tumor cells from blood. Publications | February 11, 2018 Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Magnetic nanogels (MNGs) are designed with the necessary features to function as highly efficient trapping materials for the challenging task of selectively capturing circulating tumor cells (CTCs) from the bloodstream. A key factor in this process is the ability to discriminate CTCs from hematological cells, which can be optimized by finely tuning the polymers used to link the targeting moiety to the MNGs. Here, we describe the relationship between the capturing efficiency of CTCs with overexpressed transferrin receptors and the different strategies used in polymer linkers to decorate these MNGs with transferrin (Tf). Heterobifunctional polyethylene glycol (PEG) linkers with varying molecular weights were coupled to transferrin in different ratios. Optimal results, with over 80% CTC capture efficiency, were obtained when three PEG linkers with a length of eight ethylene glycol (EG) units were used. These findings highlight the crucial role of linker design in developing efficient CTC-sorting systems. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC monitoring in breast cancer detects MRD and supports post-surgery surveillance. Publications | November 3, 2025 Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Introduction Early detection of metastasis is important for improving overall survival in breast cancer (BC) patients. Circulating tumor cells (CTCs) play a role in detecting minimal residual disease (MRD). In an ongoing cohort, we evaluated the association between CTC dynamics before and after surgery performed with curative intent. Additionally, we assessed cancer-related worry in post-surgical BC patients. Methods A total of 75 CTC tests were performed on 55 female BC patients, of whom 20 were follow-up cases. In an ongoing IEC-approved clinical cohort, 10 BC patients were enrolled using a quantitative, non-probability purposive sampling method. CTC counts, including clusters, were measured both pre-surgery and 24 hours post-surgery. PD-L1 expression on CTCs was assessed using the CDSCO-approved OncoDiscover platform. Patient-reported outcome measures (PROMs) were evaluated using the Breast-Q Cancer Worry scale, a validated subscale reflecting fear of recurrence and related concerns. Statistical analysis compared PROM scores with CTC patterns, including increase, persistence, or clearance. A paired sample t-test was applied to compare pre- and post-operative PROM scores to evaluate changes in cancer-related worry in relation to CTC counts. Results Among the 75 tests performed in 55 BC patients, 84.5% were CTC-positive, with a mean of 1.43 CTCs per test. In longitudinal monitoring of 10 female BC patients who underwent surgery, six received neoadjuvant chemotherapy (NACT) followed by breast-conserving surgery, while four underwent surgery without prior chemotherapy. Overall, 40% (4/10) showed a reduction in CTC counts, and 20% (2/10) achieved complete CTC clearance after surgery. Patients with increased post-surgery CTC counts reported a significant increase in cancer-related worry. The mean pre-surgery score was 43.9, which increased to 51.8 after surgery. These findings suggest the need for targeted emotional and psychological support in the post-surgical period and highlight the role of CTC monitoring in assessing MRD. Conclusions Monitoring CTCs strengthens their potential as an early indicator of residual disease by providing important clinical insights into tumor activity during the operative phase. Further validation is warranted to support more integrated, patient-centered care approaches aimed at reducing the burden of advanced cancer. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined ctDNA and CTC analysis improves MRD detection and cancer progression monitoring. Publications | June 3, 2024 ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Background: Post curative-intent surgery and therapy, the presence of circulating tumor DNA (ctDNA) load represents minimal residual disease (MRD). Conversely, the presence of circulating tumor cells (CTCs) in stage I–II cancer or even in disease-free survival (DFS) patients indicates occult cellular residual disease (CRD) with undetectable micrometastasis. These complementary biomarkers in patients undergoing treatment act as indicators of non-responsiveness, suggesting the need for treatment modifications. Methods: Retrospectively, we monitored a cohort of 46 cancer patients for MRD using ctDNA and CTCs who were treated or undergoing treatment (e.g., lung, breast, colon, and head and neck cancer; n = 14, 7, 6, and 4, respectively). The OncoMonitor test detected single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions). Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 in paired-end mode (150 × 2). Variant calling was performed using a proprietary bioinformatics pipeline, iCare. CTCs were isolated using the OncoDiscover platform, which possesses an anti-EpCAM antibody-based immunomagnetic system per 1.5 mL of blood. CTCs were confirmed using CK18+, PD-L1, and CD45 markers with a motorized fluorescence microscope. Results: From ctDNA analysis, 47.82% (n = 22) of patients were identified with at least one actionable genomic finding. Among these, 13.04% (n = 6) of patients showed EGFR driver mutations. Additionally, 19.56% (n = 9) of patients were identified with either EGFR driver, KRAS, or PI3K passenger mutations, while 4.34% (n = 2) were identified with ALK–EML4 fusion. The average ctDNA load obtained in patients with progressive disease (n = 26) was 8.2 molecules per 1 mL of plasma. At least one CTC was detected in 61.53% (n = 16) of progressive disease patients, with the highest count of four CTCs identified in 7.69% (n = 2) of patients. Only 30% (n = 6) of patients with stable disease were identified with at least one genomic finding from a total of 20 patients upon ctDNA analysis, with an average ctDNA load of 2.2 molecules per 1 mL of plasma. Patients with clinically progressive disease showed ctDNA load approximately fourfold higher than those with stable disease during treatment. No patients with stable disease were identified with four CTCs, as opposed to 7.69% in the progressive disease cohort during treatment. Conclusions: We observed that ctDNA and CTCs complement MRD status even after curative-intent surgery and therapy, with the potential to identify patients likely to experience disease progression. Our findings strongly indicate a positive correlation between ctDNA load, the number of detected CTCs, and disease progression based on radiological findings. These biomarkers can support practical clinical decision-making. Further studies are necessary to validate these findings and improve follow-up strategies for better clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe